Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

Journal Article · Sun Nov 01 00:00:00 EDT 2020 · Annals of Oncology

DOI:https://doi.org/10.1016/j.annonc.2020.10.599· OSTI ID:1746990

Subbiah, V.; Shen, T.; Terzyan, S. S.; Liu, X.; Hu, X.; Patel, K. P.; Hu, M.; Cabanillas, M.; Behrang, A.; Meric-Bernstam, F.; Vo, P. T. T.; Mooers, B. H. M.; Wu, J.

Not Available

• Research Organization: SLAC National Accelerator Laboratory, Menlo Park, CA (United States). Stanford Synchrotron Radiation Lightsource (SSRL)
• Sponsoring Organization: Cancer Prevention and Research Institute of Texas (CPRIT); MD Anderson Cancer Center; National Cancer Institute (NCI); National Center for Advancing Translational Sciences (NCATS); National Institute of General Medical Sciences (NIGMS); National Institutes of Health (NIH); Oklahoma Tobacco Settlement Endowment Trust; Presbyterian Health Foundation Team Science; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; USDOE Office of Science (SC), Basic Energy Sciences (BES); USDOE Office of Science (SC), Biological and Environmental Research (BER). Biological Systems Science Division
• Grant/Contract Number: AC02-76SF00515
• OSTI ID: 1746990
• Alternate ID(s): OSTI ID: 1816357
• Journal Information: Annals of Oncology, Journal Name: Annals of Oncology; ISSN 0923-7534
• Publisher: Elsevier
• Country of Publication: United Kingdom
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
60 APPLIED LIFE SCIENCES
RET-selective inhibitor
acquired resistance
crystal structure
mutation
pralsetinib
selpercatinib